register

News & Trends - Pharmaceuticals

Down-scheduling of sumatriptan and zolmitriptan to treat migraines

Health Industry Hub | May 13, 2020 |

Pharma News: The Pharmacy Guild of Australia has welcomed the decision to down- schedule sumatriptan and zolmitriptan to S3, or pharmacist-only medicines.

Sumatriptan and zolmitriptan are used to treat migraines and the National President of the Pharmacy Guild, George Tambassis, said the decision to down-schedule the medicines was a good outcome for patients.

“Patients don’t know when a migraine is coming on and so have had to try to manage their medicines by having a prescription on hand in case they needed to fill it,” he said.

“This very sensible decision by the delegate means that patients who have a stable, well-established pattern of symptoms, will be able to access sumatriptan and zolmitriptan for the acute relief of migraine when and where they need it.

Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“Importantly, being pharmacist-only medicines will ensure that patients receive the counselling and advice to ensure they are taking the medicine appropriately.

“In its decision the TGA pointed to the fact that the ‘access controls in place for a Schedule 3 medicine are appropriate and sufficient to mitigate the misuse’ of these medicines.”


Human Resources

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Health Industry Hub | May 20, 2024 |

People & Culture: Coinciding with International HR Day, Karen Newell, Senior HR Director for ANZ at Medtronic, joined Health Industry […]

More


News & Trends - MedTech & Diagnostics

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: An Australian-based medtech company announced promising results from the first-in-human study for its pulsed field ablation […]

More


News & Trends - MedTech & Diagnostics

Federal budget delivers 'mixed news' for radiologists

Federal budget delivers ‘mixed news’ for radiologists

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: The Royal College of Australian and New Zealand Radiologists (RANZCR) and the Interventional Radiology Society of […]

More


News & Trends - Pharmaceuticals

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

Health Industry Hub | May 20, 2024 |

Pharma News: The Senate Community Affairs References Committee has released its inquiry report into Equitable access to diagnosis and treatment […]

More


This content is copyright protected. Please subscribe to gain access.